Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Accolade, Inc.
  6. News
  7. Summary
    ACCD   US00437E1029

ACCOLADE, INC.

(ACCD)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-30 pm EDT
13.57 USD   +1.50%
03/23Accolade Shares Rise After Guggenheim Upgrade
MT
03/23Guggenheim Upgrades Accolade to Buy From Neutral, Price Target is $16
MT
03/06Accolade, Lyra Health Partner to Support Employees' Behavioral Health Care
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Adjusts Accolade's Price Target to $35 From $45, Maintains Overweight Rating

01/11/2022 | 08:43am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ACCOLADE, INC.
03/23Accolade Shares Rise After Guggenheim Upgrade
MT
03/23Guggenheim Upgrades Accolade to Buy From Neutral, Price Target is $16
MT
03/06Accolade, Lyra Health Partner to Support Employees' Behavioral Health Care
MT
03/06Accolade Welcomes Lyra Health to Its Trusted Partner Ecosystem
PR
02/28Accolade, Inc. : Other Events (form 8-K)
AQ
02/28Accolade, Inc. Reiterates Revenue Guidance for Fiscal Fourth Quarter Ending February 28..
CI
02/16Accolade, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
02/16Accolade, Inc. Announces Changes to Its Board of Directors
CI
02/16Michael Hilton Joins Accolade Board of Directors
AQ
02/09Jefferies Downgrades Accolade to Hold From Buy, Price Target is $14
MT
More news
Analyst Recommendations on ACCOLADE, INC.
More recommendations
Financials (USD)
Sales 2023 364 M - -
Net income 2023 -460 M - -
Net cash 2023 178 M - -
P/E ratio 2023 -2,09x
Yield 2023 -
Capitalization 988 M 988 M -
EV / Sales 2023 2,23x
EV / Sales 2024 2,06x
Nbr of Employees 2 350
Free-Float 94,8%
Chart ACCOLADE, INC.
Duration : Period :
Accolade, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCOLADE, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 13,57 $
Average target price 13,75 $
Spread / Average Target 1,33%
EPS Revisions
Managers and Directors
Rajeev Singh Chairman & Chief Executive Officer
Robert N. Cavanaugh President
Stephen H. Barnes Chief Financial Officer
Harish Naidu Chief Technology Officer
Shantanu Nundy Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ACCOLADE, INC.74.20%973
CVS HEALTH CORPORATION-20.50%95 140
HCA HEALTHCARE, INC.7.25%71 354
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY32.09%26 572
LABORATORY CORPORATION OF AMERICA HOLDINGS-5.80%19 631
QUEST DIAGNOSTICS INCORPORATED-11.48%15 416
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer